anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Mutations in KRAS and NRAS are associated with a lack of response to cetuximab and panitumumab, two biologics used for third-line therapy of metastatic colorectal cancer (mCRC). In British Columbia, Canada, eligibility for cetuximab or panitumumab was first based on single-gene KRAS testing. OncoPanel, a multi-gene next-generation sequencing panel with both KRAS and NRAS, was introduced in 2016. Our objective was to estimate the real-world cost-effectiveness of OncoPanel versus to single-gene KRAS testing to inform eligibility for cetuximab or panitumumab in mCRC.
METHODS: Using population-based administrative health data, we identified a cohort of mCRC patients who had received a KRAS or OncoPanel test, and completed prior chemotherapy in 2010-2019. We matched KRAS- and OncoPanel-tested patients (1:1) using genetic matching to balance baseline covariates. Mean and incremental 3-year costs, survival, and quality-adjusted survival were estimated using inverse-probability-of-censoring weighting and bootstrapping. We conducted scenario-based sensitivity analysis for key costs and assumptions.
FINDINGS: All OncoPanel-tested cases (n=371) were matched to a KRAS-tested comparator. In the KRAS and OncoPanel groups, respectively, 55·8 % and 41·2 % of patients were potentially eligible for cetuximab or panitumumab based on mutation status. Incremental cost and effectiveness of OncoPanel were $72 (95 % CI: -6387, 6107), -0·004 life-years (95 % CI: -0·119, 0·113), and -0·011 quality-adjusted life-years (95 % CI: -0·094, 0·075). Reductions in systemic therapy costs were offset by increased costs in other resources. Results were moderately sensitive to time horizon and changes in testing or treatment cost.
INTERPRETATION: The use of OncoPanel resulted in more precise targeting of cetuximab and panitumumab, but there was no change in incremental cost or quality-adjusted survival. Understanding the balance of costs achieved in practice can provide insight into the effect of future changes in testing policy, test cost, treatment eligibility, or drug prices in this setting.
Purpose: This study aimed to determine nursing students' opinions about human papillomavirus (HPV) infection and HPV vaccine. Methods: This is a qualitative focus group discussion study, in which a state university in Western Turkey, undergraduate nursing students are recruited through purposive sampling. The research data were collected on an online platform with the focus group interview method by using the Participant Information Form and Semistructured Interview Form. Results: Three main themes (HPV infection/vaccine perception, severity perception, and suggestions and requests/facilitators) and eight subthemes were developed based on the thematic analysis of the research findings. Conclusions: According to the findings, it was concluded that nursing students' opinions on HPV infection and HPV vaccine were affected by factors related to cultural, religious, and sexual behaviors. Based on study results, it is suggested to organize national cervical screening programs to increase public's knowledge and awareness on the subject in accordance with the sociocultural norms of the society with the agreement and cooperation of educated health service providers, policy makers, and educators.
Patients receive 89Zr-DFO-GmAb IV over 3 minutes on day 0 then undergo whole body PET/CT and SOC diagnostic contrast-enhanced CT scan on day 7. Patients also blood sample collection on study. In addition, patients may undergo bone scan and CT or MRI of the brain on study as clinically indicated.
The efficacy of varenicline tablets in smoking cessation was demonstrated in six clinical trials in which a total of 3659 chronic cigarette smokers (≥10 cigarettes per day) were treated with varenicline tablets. In all clinical studies, abstinence from smoking was determined by patient self-report and verified by measurement of exhaled carbon monoxide (CO≤10 ppm) at weekly visits. Among the varenicline-treated patients enrolled in these studies, the completion rate was 65%. Except for the dose-ranging study (Study 1) and the maintenance of abstinence study (Study 6), patients were treated for 12 weeks and then were followed for 40 weeks post-treatment. Most patients enrolled in these trials were white (79 to 96%). All studies enrolled almost equal numbers of men and women. The average age of patients in these studies was 43 years. Patients on average had smoked about 21 cigarettes per day for an average of approximately 25 years. Patients set a date to stop smoking (target quit date) with dosing starting 1 week before this date. 

Seven additional studies evaluated the efficacy of varenicline tablets in patients with cardiovascular disease, in patients with chronic obstructive pulmonary disease [see Clinical Studies ( 14.7)] , in patients instructed to select their quit date within days 8 and 35 of treatment [see Clinical Studies ( 14.4)] , patients with major depressive disorder [see Clinical Studies ( 14.9)], patients who had made a previous attempt to quit smoking with varenicline tablets, and either did not succeed in quitting or relapsed after treatment [see Clinical Studies ( 14.6)] , in patients without or with a history of psychiatric disorder enrolled in a postmarketing neuropsychiatric safety outcome trial [ see Warnings and Precautions ( 5.1), Clinical Studies ( 14.10)] , and in patients who were not able or willing to quit abruptly and were instructed to quit gradually [see Clinical studies ( 14.5)]. 

In all studies, patients were provided with an educational booklet on smoking cessation and received up to 10 minutes of smoking cessation counseling at each weekly treatment visit according to Agency for Healthcare Research and Quality guidelines.
PROBLEM TO BE SOLVED: To provide a medicine for overcoming a cancer immunosuppressive state, a composition for cancer immuno-therapy using the medicine and cancer immuno-therapy.SOLUTION: A weaning agent for cancer immunosuppression includes betulin as an effective component. The agent is used in order to recover cytotoxic activity controlled by TGF-β, or to recover cytotoxic activity controlled by PGE2. The agent can be used together with cancer immuno-therapy. The method is to increase NK cell or T cell activity in a patient who requires it and to whom the weaning agent for cancer immunosuppression is administered. The composition for cancer immuno-therapy contains an amount of betulin effective to wean cancer immunosuppression, a cancer immuno-therapeutic agent and a pharmacologically permissible carrier or excipient. The cancer immuno-therapy is at least one selected from an immunocyte, a vaccine, an immunomodulator, a biological response modifier and antibody. The cancer immuno-therapy includes administering the composition to a patient having cancer or to a patient having a possibility of cancer.
This is a multicentre, randomized, double-blind, controlled trial that aims to investigate the efficacy of multi-domain life-style intervention including low inflammatory-index diet, exercise, and cognitive training in patients with mild cognitive impairment and mild Alzheimer's disease. Patients who eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into three groups by a 1:1:1 ratio. Patients in first arm will receive multi-domain life-style intervention including low inflammatory-index diet, exercise, and cognitive training. Patients in the second arm will receive intervention of exercise and cognitive training. Patients in the third arm will receive regular health advice. We hypothesize that the multi-domain intervention will reduce impairment in the study group compared to the control group during the 2-year intervention period.
PURPOSE:To perform economical elimination of pyrogen in higher efficiency in quick and safe manner, by filtering superoxide dismutase through a specific filter membrane followed by contact of the resultant filtrate with an adsorbent for pyrogen elimination. CONSTITUTION:Firstly, PVA is intramolecularly formalized to produce a ultrafilter membrane consisting of a polymer constituted of recurring unit having a structure of the formula (with such membrane performance as to be 60-80% in the blocking rate for 0.1wt.% physiological saline solution of human serum albumin) (A). Secondly, a superoxide dismutase(SOD) sample solution containing several thousands - ten thousands ng/ml of endotoxin of several W/V% protein concentration (B) is prepared. Thirdly, the solution B is filtered through the membrane A under such conditions as 11.5-27cm<2> of the membrane area based on 50-200ml of said solution B and 2.0-4.5kg/cm<2> of filtering pressure, to obtain a filtrate (C). Thence, a nitrogen-contg. heterocyclic compound such as histidine and a water-insoluble carrier such as cellulose are mutually conjugated to prepare an adsorbent for pyrogen elimination (D). Finally, the solution C and the adsorbent D are brought into contact with each other to adsorb pyrogen on said adsorbent D, thus eliminating said pyrogen.
The present invention discloses a novel lactic acid bacteria and its use, wherein the novel lactic acid bacteria is isolated from a cereal source, has good tolerance in an alcohol environment, and can effectively achieve the effect of treating or/and preventing hyperuricemia and alcohol induced liver injury. The novel lactic acid bacteria is Lactobacillus plantarum subsp. plantarum TTL 8-16, which is deposited at Food Industry Research and Development Institute in Hsinchu, Taiwan, the deposit date is February 15, 2019 and the deposit number is BCRC 910871. Alternatively, the novel lactic acid bacteria is Lactobacillus paracasei subsp. paracasei TTL 6-10, which is deposited at Food Industry Research and Development Institute in Hsinchu, Taiwan, the deposit date is October 30, 2019, and the deposit number is BCRC 910951. The novel lactic acid bacteria disclosed in the present invention can effectively reduce the expression of inflammation-related hormones in cells, reduce the content of aspartate aminotransferase (ALT), alanine aminotransferase (AST) and triglyceride in the blood and liver, and degrade purine compounds. Thus, the novel lactic acid bacteria disclosed in the present invention have double effects of treating or/and preventing hyperuricemia and alcohol induced liver injury simultaneously. The present invention also provides a double-effect pharmaceutical composition comprising an effective amount of the above-described lactic acid bacteria and a pharmaceutically acceptable carrier. The alcohol induced liver injury is hepatic steatosis or hepatitis. The form of the pharmaceutical composition can be tablet, powder or injection. The pharmaceutically acceptable carrier includes gelatin, emulsifier, hydrocarbon mixture, water, glycerin, physiological saline, buffered physiological saline, lanolin, paraffin, beeswax, polydimethylsiloxane or ethanol. The content of triglyceride in the blood and liver can be reduced and the content of uric acid in the blood can be degraded by administering the double-effect pharmaceutical composition to an individual so as to effectively achieve the effect of treating or/and preventing hyperuricemia and alcohol induced liver injury.
Participants will receive Etavopivat 400 mg QD orally in combination with HU. The dose of HU (mg/kg) will be stable (no more than a 20% change in dosing except for weight-based changes) during the study, in the opinion of the Investigator.
Introduction Cardiopulmonary Arrest (CPA) is among the leading cause of death worldwide. Each year, 375,000 people are reported to die in Europe and 250,000 in the United States due to CPA. Early diagnosis of arrest and Cardiopulmonary Resuscitation is life-saving. However, earthquakes, one of the deadliest disasters, are among the most challenging situations that people around the world have to face. The rate of rescue of survivors from earthquake or collapsed structures is reported to decrease by 50% following 24 hours. Therefore, the first 72 hours are crucial for search and rescue operations in disasters. In earthquakes, while some of the disaster victims experience arrest at the scene due to trauma, others experience arrest in early or late periods depending on the injury site and localization. Thus, search and rescue operations should be initiated quickly, effectively and swiftly in disaster areas. Properly and efficiently administered CPR is among the most crucial life-saving emergency medical care methods. In Turkey, paramedics are also deployed to National Medical Rescue Team (NMRT) units to support search and rescue activities and provide emergency medical care. Paramedics have difficulties in maintaining chest compressions in arrest cases, especially in challenging cases in tight spaces outside the hospital. Since chest compressions are considered the essential element of CPR, their quality is thought to be affected under harsh conditions. 2015 International Liaison Committee on Resuscitation (ILCOR) recommended the compression depth as 5-6 cm and stated that 1/3 of the sternum should be compressed owing to the body mass differences of the rescuers. However, effective CPR depends on many parameters such as the number of rescuers, elapsed time, physical characteristics and muscle strength of the rescuer, high level of fitness, fatigue, weight of the rescuer, physical fitness, having a higher maximum oxygen consumption, position of the rescuer, difficult and confined space rescues. This study aimed in this context, to measure the effects of fatigue on CPR using high-quality simulators.
A single liquid phase aerosol antiperspirant composition comprises by weight from 6 to 15% of at least one dissolved inorganic astringent salt, from 6 to 24% of water, from 30 to 60% of at least one alcohol containing up to 6 carbon atoms, from 15 to 45% of an aerosol propellant and from 0.25 to 6% of at least one alkali metal salt of a benzene, toluene or xylene sulphonic acid.  The astringent may be zirconium chloride, hydroxychloride or sulphate, zinc chloride, sulphate or phosphate, aluminium chloride, sulphate or oxychloride, or their hydrates, e.g. AlCl3.6H3O or ferric chloride or ferrous sulphate: preferred is aluminium chlorhydrate. A mixture of zirconyl hydroxy chloride with the aluminium chlorhydrate complex disclosed in Specification 835,385 may be used.  Suitable alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, ethylene glycol or propylene glycol.  Propellants may include dimethyl ether and various chlorofluorohydrocarbons. Anti-bacterial agents, e.g. hexachlorophene and buffers, e.g. urea may be included.ALSO:A single liquid phase aerosol antiperspirant composition comprises by weight from 6 to 15% of at least one dissolved inorganic astringent salt, from 6 to 24% of water, from 30 to 60% of at least one alcohol containing up to 6 carbon atoms, from 15 to 45% of an aerosol propellant and from 0.25 to 6% of at least one alkali metal salt of a benzene, toluene or xylene sulphonic acid. The astringent may be zirconium chloride, hydroxychloride or sulphate, zinc chloride, sulphate or phosphate, aluminium chloride, sulphate or oxychloride, or their hydrates e.g. AlCl3.  6H3O or ferric chloride or ferrous sulphate: preferred is aluminium chlorhydrate.  A mixture of zirconyl hydroxy chloride with the aluminium chlorhydrate complex disclosed in Specification No. 835385 may be used.  Suitable alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, ethylene glycol or propylene glycol. Propellants may include dimethyl ether and various chlorofluorohydrocarbons.  Anti bacterial agents e.g. hexachlorophene and buffers e.g. urea may be included.
FIELD: veterinary. SUBSTANCE: method involves the utilization of waste in production of butylcholine esterase from equine blood containing albumin as ballast protein. Then protein is dissolved in apyrogenic water at pH 9-12. Dialysis is carried out at 10-15 C and pH 7-9. Then glucose and sodium chloride were added to the prepared solution up to concentrations 5-20% and 0.8-1%, respectively, followed by filtration and sterilization. EFFECT: improved method of albumin preparing. 2 tbl
PROBLEM TO BE SOLVED: To obtain the subject tablet capable of remarkably increasing the volume and staying for a long time in abdomen and/or a first part of gastrointestinal duct and suitable for oral administration to human, etc., by contact with a body fluid. SOLUTION: This tablet releases the active ingredient at a selectively controlled rate mainly in the first part of stomach, intestine duodenum level and small intestine and the tablet is composed of a multilayer comprising the following layers (a), (b) and (c) formed by compression. The layer (a) is a layer capable of increasing the volume in a width of at least 50% based on total volume of the tablet by swelling when brought into contact with the gastric juice and is composed of a compressed granule mixture of a biocompatible hydrophilic polymer and a swelling polymer (in an amount of 1-90wt.% based on layer weight).  The layer (b) is adjacent to the layer (a) and contains an active ingredient (e.g. prazosin) and composed of a biodegradable and biocompatible polymer substance and other adjuvant and isolates the active ingredient in a time interval determined by in vitro preliminary test. The layer (c) is adjacent to the layer (b) and has same composition as the layer (a), as necessary formed and controls release of active ingredient of the adjacent layer (b).
An automated method, as well as computer-implemented systems, apparatus and software products, to predict patient demand in a medical facility. A database contains historical data of patient demand during one or more past time periods. At least two distinguishing characteristics are associated ( 202 ) with a specified time period of interest, the first characterising a day within which the time period occurs, and the second characterising a timeframe within which the day occurs. Corresponding historical data is extracted ( 204 ) having equivalent distinguishing characteristics. A computational predictive model is applied ( 206 ) to the extracted data, to generate a prediction of patient demand. The predicted demand is output ( 208 ), for example to a suitable visual display. The invention may be applied, for example, to improve the efficiency of operations in medical facility emergency departments.
A system and method are provided for applying guidelines to data and providing self-assessment ability. Guideline data is stored in a data storage component, along with user data. The user data represents both quantitative data and qualitative self assessment data. In a self-assessment system and method, a graphical user interface is provided along with a target image and factor icons. The icons are adapted to be moved onto a position on the target image representative of an entity's self assessment of performance relative to the corresponding factor. A subset of actionable alternatives are selected and displayed based on the self-assessment data and the guidelines.
The present invention discloses a medicine for treating insomnia and a preparation method thereof. The medicine is prepared from the main raw materials of 1 to 4 parts by weight of succinum, 6 to 10 parts by weight of spine date seed, 6 to 10 parts by weight of tuber fleeceflower stem, 6 to 10 parts by weight of silktree albizzia bark, 2 to 6 parts by weight of nacre, 2 to 6 parts by weight of dragon tooth, 0.5 to 3 parts by weight of thinleaf milkwort root and 0.5 to 3 parts by weight of grassleaf sweetflag rhizome, and is added with auxiliary materials of 1 to 4 parts by weight of rehmanniae, 1 to 4 parts by weight of coptis, 0.5 to 3 parts by weight of angelica and 0.5 to 3 parts by weight of tuckahoe. The main raw materials and the auxiliary materials are prepared by scientifically extracting and concentrating. The present invention can be prepared into any formulation for oral administration. The medicine of the present invention has the functions of tranquilizing the spirit, stabilizing the mind, clearing heat, cooling blood, dispelling phlegm, inducing resuscitation, etc. The present invention is used for treating various kinds of insomnia and is convenient to take orally. The present invention has conspicuous curative effect, high cure rate and no toxic or side effect.
As a noninvasive treatment modality, high-intensity focused ultrasound (HIFU)-induced antitumor immune responses play a vital role in surgery prognosis. However, limited response intensity largely hinders postoperative immunotherapy. Herein, a hypoxia-specific metal-organic framework (MOF) nanosystem, coordinated by Fe3+, hypoxic-activated prodrug AQ4N, and IDO-1 signaling pathway inhibitor NLG919, is developed for the potentiating immunotherapy of HIFU surgery. The loaded AQ4N enhances the photoacoustic imaging effects to achieve accurate intraoperative navigation. Within the HIFU-established severe hypoxic environment, AQ4N is activated sequentially, following which it cooperates with Fe3+ to effectively provoke immunogenic cell death. In addition, potent NLG919 suppresses IDO-1 activity and degrades the immunosuppressive tumor microenvironment aggravated by postoperative hypoxia. In vivo studies demonstrate that the MOF-mediated immunotherapy greatly inhibits the growth of primary/distant tumors and eliminates lung metastasis. This work establishes a robust delivery platform to improve immunotherapy and the overall prognosis of HIFU surgery with high specificity and potency.
BACKGROUND: There is a scarcity of studies on the association between physical multimorbidity and lower levels of physical activity among older adults from low- and middle-income countries, while the potential mediating variables in this association are largely unknown.
METHODS: Cross-sectional, community-based, nationally representative data from the World Health Organization Study on global AGEing and adult health were analyzed. Data on 11 chronic physical conditions were collected. Scoring <150 minutes of moderate- to high-intensity physical activity per week was considered low physical activity. Multivariable logistic regression and mediation analysis were done to assess associations and quality of life measures which might influence these associations.
RESULTS: Data on 14,585 people aged ≥65 years were analyzed (mean [SD] age 72.6 (11.5) y, maximum age 114 y; 55.0% women). After adjustment for potential confounders, compared with no chronic conditions, ≥3 conditions were associated with a significant 1.59 to 2.42 times higher odds for low physical activity. Finally, mobility mediated the largest proportion of the association between ≥3 chronic physical conditions and low physical activity (mediated percentage 50.7%), followed by activities of daily living disability (30.7%), cognition (24.0%), affect (23.6%), and pain/discomfort (22.0%).
CONCLUSIONS: Physical multimorbidity was associated with higher odds for low physical activity among older adults residing in low- and middle-income countries. Mobility, disability, cognition, affect, and pain/discomfort explained the largest proportion of this association. Given the universal benefits of regular and sustained participation in physical activity, it would be prudent to implement interventions among older people with physical multimorbidity to increase levels of physical activity. Future studies should assess the impact of addressing the identified potential mediators among people with multimorbidity on physical activity levels.